表紙
市場調查報告書

腎上腺素注射器的全球市場:2020年∼2024年

Global Epinephrine Autoinjector Market 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 282669
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
腎上腺素注射器的全球市場:2020年∼2024年 Global Epinephrine Autoinjector Market 2020-2024
出版日期: 2020年04月21日內容資訊: 英文 120 Pages
簡介

全球腎上腺素注射器市場在2019年∼2026年間,預測將以7%的年複合成長率推移,市場規模達到7億6,251萬美元的規模。過敏的罹患率上升,及技術進步,行銷策略的擴大等將促進這個市場成長。

本報告提供全球腎上腺素注射器市場調查,提供市場概要,各劑量·年齡層·終端用戶·各地區的市場規模的變化與預測,市場成長要素及課題,競爭情形,主要企業的簡介等全面性資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模
  • 市場預測

波特的五力分析

市場區隔:各劑量

  • 市場區隔:各劑量
  • 市場比較:各劑量
  • 0.30 gm
  • 0.15 gm
  • 0.50 gm
  • 市場機會:各劑量

市場區隔:各年齡層

  • 市場區隔:各年齡層

市場區隔:各終端用戶

  • 市場區隔:各終端用戶
  • 市場比較:各終端用戶
  • 醫院·診療所
  • 個人
  • 市場機會:各終端用戶

客戶形勢

  • 概要

市場區隔:各地區

  • 市場區隔:各地區
  • 市場比較:各地區
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會:各地區
  • 需求促進因素 - 需求主導的成長
  • 市場課題
  • 市場趨勢

業者情勢

  • 業者情勢
  • 創造性破壞狀況
  • 競爭模式

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Adamis Pharmaceuticals Corp.
  • ALK-Abello AS
  • Amneal Pharmaceuticals Inc.
  • Bausch Health Companies Inc.
  • kaleo Inc.
  • Lincoln Medical Ltd.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR43297

Technavio has been monitoring the epinephrine autoinjector market and it is poised to grow by $ 762.51 mn during 2020-2024 progressing at a CAGR of 7% during the forecast period. Our reports on epinephrine autoinjector market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of allergies, technological advances and marketing strategies. In addition, increasing prevalence of allergies is anticipated to boost the growth of the market as well.

The epinephrine autoinjector market analysis include end-user segment and geographic landscapes

Technavio's ‘ epinephrine autoinjector market ’ is segmented as below:

By End-user:

  • Hospitals
  • Clinics
  • Individuals

By Geographic Landscapes:

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the tentative product launches as one of the prime reasons driving the epinephrine autoinjector market growth during the next few years. Also, growing awareness about epinephrine autoinjectors and patient assistance programs will lead to sizable demand in the market.

"Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our epinephrine autoinjector market covers the following areas:

  • Epinephrine autoinjector market sizing
  • Epinephrine autoinjector market forecast
  • Epinephrine autoinjector market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading epinephrine autoinjector market vendors that include Adamis Pharmaceuticals Corp., ALK-Abello AS, Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., kaleo Inc., Lincoln Medical Ltd., Mylan NV, Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.. Also, the epinephrine autoinjector market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five Force Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Dosage

  • Market segments
  • Comparison by Dosage
  • 0.30gm - Market size and forecast 2019-2024
  • 0.15gm - Market size and forecast 2019-2024
  • 0.50gm - Market size and forecast 2019-2024
  • Market opportunity by Dosage

Market Segmentation by Age Group

  • Market segmentation by Age Group

Market Segmentation by End-user

  • Hospitals and clinics
  • Individuals

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Volume driver - demand-led growth
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption
  • Competitive Scenario

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Adamis Pharmaceuticals Corp.
  • ALK-Abello AS
  • Amneal Pharmaceuticals Inc.
  • Bausch Health Companies Inc.
  • kaleo Inc.
  • Lincoln Medical Ltd.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Other1 - Market share 2019-2024 (%)
  • 22: Comparison by Other1
  • 23: 0.30gm - Market size and forecast 2019-2024 ($ million)
  • 24: 0.30gm - Year-over-year growth 2019-2024 (%)
  • 25: 0.15gm - Market size and forecast 2019-2024 ($ million)
  • 26: 0.15gm - Year-over-year growth 2019-2024 (%)
  • 27: 0.50gm - Market size and forecast 2019-2024 ($ million)
  • 28: 0.50gm - Year-over-year growth 2019-2024 (%)
  • 29: Market opportunity by Other1
  • 30: Customer landscape
  • 31: Market share by geography 2019-2024 (%)
  • 32: Geographic comparison
  • 33: North America - Market size and forecast 2019-2024 ($ million)
  • 34: North America - Year-over-year growth 2019-2024 (%)
  • 35: Europe - Market size and forecast 2019-2024 ($ million)
  • 36: Europe - Year-over-year growth 2019-2024 (%)
  • 37: Asia - Market size and forecast 2019-2024 ($ million)
  • 38: Asia - Year-over-year growth 2019-2024 (%)
  • 39: ROW - Market size and forecast 2019-2024 ($ million)
  • 40: ROW - Year-over-year growth 2019-2024 (%)
  • 41: Key leading countries
  • 42: Market opportunity by geography ($ million)
  • 43: Impact of drivers and challenges
  • 44: Vendor landscape
  • 45: Landscape disruption
  • 46: Industry risks
  • 47: Vendors covered
  • 48: Market positioning of vendors
  • 49: Adamis Pharmaceuticals Corp. - Overview
  • 50: Adamis Pharmaceuticals Corp. - Product and service
  • 51: Adamis Pharmaceuticals Corp. - Key offerings
  • 52: Adamis Pharmaceuticals Corp. - Key customers
  • 53: Adamis Pharmaceuticals Corp. - Segment focus
  • 54: ALK-Abello AS - Overview
  • 55: ALK-Abello AS - Product and service
  • 56: ALK-Abello AS - Key offerings
  • 57: ALK-Abello AS - Key customers
  • 58: ALK-Abello AS - Segment focus
  • 59: Amneal Pharmaceuticals Inc. - Overview
  • 60: Amneal Pharmaceuticals Inc. - Business segments
  • 61: Amneal Pharmaceuticals Inc. - Key offerings
  • 62: Amneal Pharmaceuticals Inc. - Key customers
  • 63: Amneal Pharmaceuticals Inc. - Segment focus
  • 64: Bausch Health Companies Inc. - Overview
  • 65: Bausch Health Companies Inc. - Business segments
  • 66: Bausch Health Companies Inc. - Key offerings
  • 67: Bausch Health Companies Inc. - Key customers
  • 68: Bausch Health Companies Inc. - Segment focus
  • 69: kaleo Inc. - Overview
  • 70: kaleo Inc. - Product and service
  • 71: kaleo Inc. - Key offerings
  • 72: kaleo Inc. - Key customers
  • 73: kaleo Inc. - Segment focus
  • 74: Lincoln Medical Ltd. - Overview
  • 75: Lincoln Medical Ltd. - Product and service
  • 76: Lincoln Medical Ltd. - Key offerings
  • 77: Lincoln Medical Ltd. - Key customers
  • 78: Lincoln Medical Ltd. - Segment focus
  • 79: Mylan NV - Overview
  • 80: Mylan NV - Business segments
  • 81: Mylan NV - Key offerings
  • 82: Mylan NV - Key customers
  • 83: Mylan NV - Segment focus
  • 84: Novartis AG - Overview
  • 85: Novartis AG - Business segments
  • 86: Novartis AG - Key offerings
  • 87: Novartis AG - Key customers
  • 88: Novartis AG - Segment focus
  • 89: Pfizer Inc. - Overview
  • 90: Pfizer Inc. - Business segments
  • 91: Pfizer Inc. - Key offerings
  • 92: Pfizer Inc. - Key customers
  • 93: Pfizer Inc. - Segment focus
  • 94: Teva Pharmaceutical Industries Ltd. - Overview
  • 95: Teva Pharmaceutical Industries Ltd. - Business segments
  • 96: Teva Pharmaceutical Industries Ltd. - Key offerings
  • 97: Teva Pharmaceutical Industries Ltd. - Key customers
  • 98: Teva Pharmaceutical Industries Ltd. - Segment focus
  • 99: Currency conversion rates for US$
  • 100: Research Methodology
  • 101: Validation techniques employed for market sizing
  • 102: Information sources
  • 103: List of abbreviations